ArticleNeuro-oncology practice2023
DICER1-associated central nervous system sarcoma: A comprehensive clinical and genomic characterization of case series of young adult patients.
Article in Neuro-oncology practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 20 citations in OpenAlex.
- Primary CNS sarcoma, DICER1-mutant with rhabdomyoblastic differentiation arising within the thoracic spine: illustrative case.Journal of neurosurgery. Case lessons · 2026Article
- Case Report:Frontiers in oncology · 2026Article
- Primary intracranial sarcomas in Peruvian children: a high-incidence clinicopathological series from a National Reference Center.Ecancermedicalscience · 2026Article
- RAS pathway targeted therapy in patients with DICER1-associated sarcomas.NPJ precision oncology · 2025Article
- Mesenchymal Nonmeningothelial Tumors of the CNS: Evolving Molecular Landscape and Implications for Neuroradiologists.AJNR. American journal of neuroradiology · 2025Review
- Review
- Alternative driver pathways in peripheral nerve sheath tumors - including DICER1 and/or KRAS alterations.The Journal of pathology · 2025Article
- Case Report: Primary intracranial high-grade myofibroblastic sarcoma and literature review.Frontiers in oncology · 2025Article
- Primary intracranial sarcoma associated with DICER1 mutant: a case report and preclinical investigation.Brain tumor pathology · 2025Article
- Primary Intracranial Sarcomatoid Yolk Sac Tumor With Unique Histology: A Case Report.Case reports in pathology · 2025Article
- Imaging Features of Primary Intracranial Sarcoma withAJNR. American journal of neuroradiology · 2024Article
- Central nervous system tumors of uncertain differentiation.World neurosurgery: X · 2024Review
- Awake craniotomies in South America: Advancements, challenges, and future prospects.Journal of central nervous system disease · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: We collected clinical, histological, and molecular data from eight young adults with DCS. Genomic analysis was performed by Next-generation Sequencing (NGS). Subsequently, an additional germline variants analysis was completed. In addition, an NGS analysis on post-progression tumor tissue or liquid biopsy was performed when available. Multiple clinicopathological characteristics, treatment variables, and survival outcomes were assessed. Results: Median age was 20 years. Most lesions were supratentorial. Histology was classified as fusiform cell sarcomas (50%), undifferentiated (unclassified) sarcoma (37.5%), and chondrosarcoma (12.5%). Germline pathogenic Conclusions: DCS is an aggressive tumor with limited therapeutic options that requires a comprehensive diagnostic approach, including molecular characterization. Most cases had mutations in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.